Rivastigmine
Brand names: Exelon, Rivastigmine
Part of: Dementia drugs
At a glance
- Medicare prescriptions, 2024
- 281,071
- Medicare drug cost
- $50.8M
- Average cost per prescription
- $181
- Clinicians who prescribed it
- 9,445
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
EXELON PATCH is an acetylcholinesterase inhibitor indicated for treatment of: • Mild, moderate, and severe dementia of the Alzheimer’s type (AD). • Mild-to-moderate dementia associated with Parkinson’s disease (PD). 1.1 Alzheimer’s
From the FDA-approved prescribing information (label dated May 2024). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Neurology 35.3%
- Internal Medicine 16.4%
- Nurse Practitioners 15.1%
- Family Medicine 12.4%
- Psychiatry 5.1%
- Geriatric Medicine 4.4%
- Physician Assistants 3.9%
- General Practice 2.7%
- Psychiatric Nurse Practitioners 1.6%
- Hospitalist 0.5%
- Emergency Medicine 0.4%
- Physical Medicine & Rehabilitation (PM&R) 0.3%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 33% from 2019 to 2024.
Biggest change by state since 2019
- Puerto Rico +19%
- Mississippi −1%
- Minnesota −8%
- Maryland −18%
- Wisconsin −19%
- South Carolina (smallest change) −52%
- Missouri (smallest change) −51%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
American Health PAckaging
| Strength | Looks like | Imprint |
|---|---|---|
| 1.5 mg | orange capsule, 17 mm | RDY 352 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
No FDA-reported recalls since 2020.
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.